The Food and Drug Administration (FDA) has refused to review Moderna’s experimental flu shot, mRNA-1010, citing issues with the study design despite previous agency approval. Moderna stated the FDA did not identify any safety or efficacy concerns and plans to meet with the agency to discuss a path forward. This decision, which contrasts with prior feedback, occurs amidst broader shifts in U.S. vaccine regulation influenced by prominent vaccine skeptic Robert F. Kennedy Jr. and the return of FDA vaccine regulator Vinay Prasad, who has advocated for tighter vaccine rules. Despite this setback, Moderna’s stock saw a slight dip, but the company expects approval for its flu shot by late 2026 or late 2027, pending international reviews.
Read More
The Food and Drug Administration (FDA) is cautioning consumers against purchasing certain cans of Genova Yellowfin Tuna due to potential contamination risks. These cans, which were part of a previous recall due to defective lids, were inadvertently shipped to several grocery store chains across nine states. The suspect cans, identified by specific UPC and code numbers, may contain clostridium botulinum, a dangerous form of food poisoning. Consumers are urged to discard the affected tuna products immediately or seek a refund from the point of purchase and to seek immediate medical attention if they feel unwell.
Read More
The FDA has recently approved two new oral antibiotics, zoliflodacin and gepotidacin, for the treatment of gonorrhea, marking the first new treatments in decades. These approvals come amid rising cases of gonorrhea and increasing antibiotic resistance to existing treatments. Both medications offer the advantage of oral administration, potentially improving patient access and convenience compared to the current injectable standard of care. Clinical trials demonstrated comparable efficacy and safety profiles for the new drugs.
Read More
The FDA is reportedly planning to issue “black box” warnings for COVID-19 vaccines, a move that has shocked outside experts. This plan, orchestrated by Dr. Vinay Prasad, is intended to warn about potential risks. This plan has sparked controversy due to the lack of transparency and a potential undermining of the vaccines’ safety, with many public health experts demanding supporting data. Critics worry this action may erode public trust in vaccines, potentially leading to unnecessary loss of life, especially since the move does not appear to follow established scientific processes.
Read More
The FDA’s leading vaccine regulator has announced stricter approval processes, citing a review that linked Covid vaccines to the deaths of at least ten children, primarily due to myocarditis. This shift involves re-evaluating existing vaccination policies, potentially limiting simultaneous vaccinations, and demanding more robust safety data. Experts suggest these changes could significantly slow the vaccine approval pipeline and may even discourage innovation in vaccine research. Critics, including former FDA officials and independent scientists, question the lack of detailed evidence supporting these claims and the potential politicization of the agency’s approach, emphasizing the importance of thorough investigation and peer review.
Read More
A recent outbreak of infant botulism has been linked to ByHeart brand powdered formula, with at least 37 infants affected. The California Department of Health found Clostridium botulinum bacteria in an opened can of formula, leading to a nationwide recall of specific batches, and eventually all ByHeart products. Despite the recall, the FDA reports that ByHeart formula remains on store shelves in multiple states, including major retailers. Investigations are underway to determine how the formula became contaminated, with concerns that the outbreak may expand as officials review earlier cases.
Read More
The Food and Drug Administration (FDA) is removing black box safety warnings from hormone therapy treatments for menopause, citing a review of recent scientific evidence. The warnings, which previously highlighted risks of cancer, dementia, heart attacks, and strokes, will be removed to increase accessibility and facilitate shared decision-making between patients and clinicians. Despite this change, systemic estrogen products still carry potential risks, and the American College of Obstetrics and Gynecology (ACOG) emphasizes the importance of individual consultations. The FDA’s decision, however, has drawn some criticism, as it bypassed the usual advisory committee process.
Read More
A recall has been issued for specific lots of ByHeart Whole Nutrition Infant Formula after the FDA linked the product to a multi-state infant botulism outbreak. The recall includes two lots of the powdered formula with December 1 “use by” dates, following reports of 13 children being hospitalized since August. The FDA is advising parents and caregivers to discard the affected product and monitor infants for botulism symptoms, with cases reported across ten states. Although ByHeart has not confirmed a direct link through their own testing, they are taking this proactive measure, and the FDA is investigating the source of contamination.
Read More
In a recent ruling, a federal judge in Hawaii found that the U.S. Food and Drug Administration unlawfully restricted access to mifepristone, a medication used for abortions and miscarriage management. The court determined the FDA violated the law by failing to provide a justified explanation for maintaining its restrictions, which include special certifications for prescribers and pharmacies. The ACLU, which brought the lawsuit, argued that the restrictions disproportionately impact patients with limited healthcare access, highlighting the medication’s safety and effectiveness. Although the FDA is instructed to reconsider its stance, the restrictions currently remain in place as the case navigates ongoing political pressures surrounding the medication.
Read More
Health Secretary Robert F. Kennedy Jr. stated there is insufficient evidence to definitively link Tylenol to autism, despite previous warnings from the White House regarding its use during pregnancy. This comes after the state of Texas sued Tylenol maker Kenvue, alleging failure to warn consumers about potential health risks. Kennedy suggests a cautious approach to Tylenol use during pregnancy, citing suggestive studies while acknowledging a lack of conclusive proof of causation. The FDA is also reviewing the issue, acknowledging conflicting studies and planning to initiate a safety label change for acetaminophen.
Read More
John Q. Hosedrinker